



Our Reference: BLA 125611/0

**Novo Nordisk Inc.
Attention: Ms. Patricia D. Wilson
April 10, 2017
Sent by email**

Dear Ms. Wilson:

We are reviewing your May 16, 2016 biologics license application for Coagulation Factor IX (Recombinant), GlycoPEGylated. We determined that the following revisions to your labels are necessary to continue our review:

- 1. Please make the changes in the Prescribing Information according to the attached word document. Please accept all those changes where agreement has been reached but leave your comments where further discussion is needed. Please submit both the clean and annotated versions of the revised labeling in Word and PDF formats.**
- 2. Please expect additional comments with the next round of review when you submit a clean version of the revised labeling.**

The review of this application is on-going and issues may be added, expanded upon, or modified.

Please submit your response for this request as an amendment to this file by April 17, 2017, referencing the date of this request. Please include both a red-line strike out and clean copy of the revised package insert in WORD format. If you anticipate you will not be able to respond by this date, please contact the Agency immediately so a new response date can be identified.

If we determine that your response to this information request constitutes a major amendment, we will notify you in writing.

The action due date for this file is June 3, 2017.

Please send an acknowledgement message for receipt of this request.

If you have any questions, please contact me at (240) 402-8443.

Sincerely,
Edward Thompson
Regulatory Project Manager
FDA/CBER/OTAT/DRPM

THIS DOCUMENT IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER APPLICABLE LAW.
If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify us by telephone and return it to us at the above address by mail.
Thank you.